Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

@article{Kesteren2000PharmacokineticsAP,
  title={Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.},
  author={Charlotte van Kesteren and Esteban Cvitkovic and A. Taamma and Luis L{\'o}pez-L{\'a}zaro and Jos{\'e} Mar{\'i}a Jimeno and Cecilia G Guzm{\'a}n and R A Math t and Jan H. M. Schellens and J. L. Misset and Etienne G. C. Brain and Michel J. X. Hillebrand and Howard Rosing and Jos H. Beijnen},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2000},
  volume={6 12},
  pages={
          4725-32
        }
}
Ecteinascidin (ET) 743 is an anticancer agent derived from the Caribbean tunicate Ecteinascidia turbinata. Preclinical studies revealed activity of ET-743 against different tumor types. A Phase I clinical trial was designed with ET-743 to identify the maximum tolerated dose and dose-limiting toxicities (DLTs). Furthermore, the pharmacokinetics of ET-743 and relationships with pharmacodynamics were evaluated. Adult patients with solid, resistant tumors received ET-743 as a 24-h i.v. infusion… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 1998
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Cytochrome P450 catalyzed metabolism of Ecteinascidin 743 by rat and human liver microsomes

M. J. Kuffel, J. M. Reid, M. M. Ames
  • Proc. Am. Assoc. Cancer Res.,
  • 1997
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Final results of a Phase I study of Ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients

E. Cvitkovic, M. Riofrio, +8 authors J. L. Misset
  • (pts.). Proc. Am. Soc. Clin. Oncol.,
  • 1999
VIEW 1 EXCERPT

Phase I trial of dolastatin-10 (NSC 376128) with advanced solid tumors

H. C. Pitot, E. A. McElroy, +10 authors M. M. Ames
  • Clin. Cancer Res.,5:
  • 1999